Who is next in line to receive the COVID-19 vaccine?
3 months 2 weeks 3 days ago
Thursday, December 31 2020
Dec 31, 2020
December 31, 2020 9:23 PM
December 31, 2020
in
News - Local
Share:
The Department of State Health Services announced that people 65 and older and anyone 16 years and older with a chronic medical condition are next in line for the COVID-19 vaccine.
People diagnosed with cancer, chronic kidney disease, Chronic Obstructive Pulmonary disease (COPD) or any other chronic medical conditions are in the group referred to as Phase 1-B . Health Care workers came first because we need them to be able to take care of the sick, Starr County Health Authority Dr. Antonio Falcon said. Immediately after that comes the highest risk of our population, which are the residents of long-term care facilities. That group has suffered the most death.
Local News: Front-line healthcare workers vaccinated at Fitzgibbon and TLC (12/29/20) marshallnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marshallnews.com Daily Mail and Mail on Sunday newspapers.
12 Days of Christmas: Asthma NZ - helping asthmatics to breathe easier
18 Dec, 2020 04:00 PM
3 minutes to read
Tara Gordon with 3-year-old daughter Quinn who suffers from asthma and Bekitmba Maseko from the Asthma Foundation. Photo / Greg Bowker
Tara Gordon with 3-year-old daughter Quinn who suffers from asthma and Bekitmba Maseko from the Asthma Foundation. Photo / Greg Bowker
NZ Herald
The Herald is profiling 12 charities awarded $8333 grants from Auckland Airport s Twelve Days of Christmas programme – now in its 13th year. The $100,000 funding comes from generous travellers who donate money at the airport.
The moment her baby Quinn was admitted to hospital with an asthma attack was the scariest of Tara Gordon s life.
Search jobs 16-Dec-2020 First patients dosed in Phase III trials evaluating Fasenra in hypereosinophilic syndrome, eosinophilic esophagitis and eosinophilic granulomatosis with polyangiitis
New clinical trial also announced for Fasenra
in eosinophilic gastritis/eosinophilic gastroenteritis
The first patients have been dosed in
Fasenra (benralizumab) Phase III trials in three rare eosinophilic diseases: hypereosinophilic syndrome (HES), eosinophilic esophagitis (EoE) and eosinophilic granulomatosis with polyangiitis (EGPA)
AstraZeneca will also initiate a Phase III trial to investigate the potential of
Fasenra in an additional rare eosinophilic disease: eosinophilic gastritis/eosinophilic gastroenteritis (EG/EGE). This trial extends the
Fasenra clinical programme to nine diseases where eosinophils play an important role, in addition to severe asthma.